nach oben

Erschienen in:

14.06.2015 | Original Article

Tumor-infiltrating CD45RO⁺ memory cells are associated with a favorable prognosis breast cancer

verfasst von: Reina Yajima, Toshiki Yajima, Takaaki Fujii, Yasuhiro Yanagita, Tomomi Fujisawa, Takeshi Miyamoto, Soichi Tsutsumi, Misa Iijima, Hiroyuki Kuwano

Erschienen in: Breast Cancer | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

CD45RO is a marker for memory lymphocytes. Whether CD45RO⁺ tumor-infiltrating lymphocytes (TILs) prevent breast cancer recurrence is unclear.

Methods

In the present study, we evaluated CD45RO expression in TILs as a predictor of prognosis in 98 patients with breast cancer who underwent radical surgery without neoadjuvant chemotherapy. Patients were classified as CD45RO⁺/TILs^High or CD45RO⁺/TILs^Low based on median immunohistochemistry levels.

Results

CD45RO⁺/TILs^High were associated with smaller tumor size. The CD45RO⁺/TILs^High group also had significantly fewer metastatic lymph nodes (P = 0.0082) and fewer peritumoral lymphatic invasions (P = 0.0284). The CD45RO⁺/TILs^High group enjoyed longer recurrence-free survival (P = 0.0453) but not cancer-specific survival (P = 0.0640) in univariate analysis.

Conclusions

These results suggested that CD45RO⁺ effector cells may both help eradicate local tumors and prevent metastases to the lymphatic systems in breast cancer patients. High ratio of CD45RO expressing TILs was associated with recurrence-free survival improvement and a trend toward cancer-specific survival improvement in breast cancer patients.

Sallusto F, Geginat J, Lazavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63.CrossRefPubMed

Vazquez-Cintron EJ, Monu NR, Frey AB. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol. 2010;185:7133–40.CrossRefPubMedPubMedCentral

Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011;105:1191–6.CrossRefPubMedPubMedCentral

Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, et al. Clinical impact of tumor-infiltrating memory T cells in esophageal squamous cell carcinoma. Clin Exp Immunol. 2012;168:186–91.CrossRefPubMedPubMedCentral

Wakatsuki K, Sho M, Yamato I, Takayama T, Matsumoto S, Tanaka T, et al. Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer. Oncol Rep. 2013;29:1756–62.PubMed

Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumor-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704–11.CrossRefPubMedPubMedCentral

Pagès F, Burger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.CrossRefPubMed

Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944–51.CrossRefPubMed

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.CrossRefPubMed

10.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMed

11.

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumor-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.CrossRefPubMedPubMedCentral

12.

Chew A, Salama P, Robbshaw A, Klopcic B, Zeps N, Platell C, et al. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. PLoS One. 2011;6:e22047.CrossRefPubMedPubMedCentral

13.

Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer. 2010;116:5188–99.CrossRefPubMed

14.

Gao Q, Zhou J, Wang XY, Qiu SJ, Song K, Huang XW, et al. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann Surg Oncol. 2012;19:455–66.CrossRefPubMed

15.

Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thor Cardiovasc Surg. 2008;135:823–9.CrossRef

16.

The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara; 2012.

17.

Ménard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997;3:817–9.PubMed

18.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805.CrossRefPubMed

19.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611–8.CrossRefPubMedPubMedCentral

20.

Piersma J, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354–61.CrossRefPubMed

21.

Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967–72.CrossRefPubMedPubMedCentral

22.

Aaltomaa S, Lipponen P, Eskelinen M, Marin S, Alhava E, Syrjänen K. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28A:859–64.CrossRefPubMed

23.

Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.CrossRefPubMedPubMedCentral

24.

Mahmoud S, Lee A, Ellis I, Green A. CD8+ T lymphocytes infiltrating breast cancer: a promising new prognostic marker? Oncoimmunology. 2012;1:364–5.CrossRefPubMedPubMedCentral

25.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3⁺ regulatory T cells. Clin Cancer Res. 2008;14:2413–20.CrossRefPubMed

26.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.CrossRefPubMedPubMedCentral

27.

Péguillet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, Piperno-Neumann S, et al. High number of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204–16.CrossRefPubMed

28.

Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumor-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun. 2010;10:3.PubMedPubMedCentral

29.

Tamiolakis D, Simopoulos C, Cheva A, Lambropoulou M, Kotini A, Jivannakis T, et al. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur J Gynecol Oncol. 2002;23:433–6.

30.

Smith SH, Brown MH, Rowe D, Beverley PC. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. Immunology. 1986;58:63–70.PubMedPubMedCentral

Titel: Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer
verfasst von: Reina Yajima
Toshiki Yajima
Takaaki Fujii
Yasuhiro Yanagita
Tomomi Fujisawa
Takeshi Miyamoto
Soichi Tsutsumi
Misa Iijima
Hiroyuki Kuwano
Publikationsdatum: 14.06.2015
Verlag: Springer Japan
Erschienen in: Breast Cancer / Ausgabe 4/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-015-0622-y

Springer Medizin

Tumor-infiltrating CD45RO⁺ memory cells are associated with a favorable prognosis breast cancer